secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2025-01-30T23:59:59+00:00
Accession:  0000950170-25-010802
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed doses first patient in Phase 3 Panorama study of MM120 for GAD; data H2 2026
--------------------------------------------------------------------------------

- First patient dosed in Panorama, second Phase 3 study of MM120 ODT (LSD) for generalized anxiety disorder.
- Study will enroll ~250 participants at US/European sites; randomized 2:1:2 to 100µg, 50µg, or placebo.
- Primary endpoint: change from baseline in HAM-A at Week 12 for MM120 ODT 100µg vs placebo.
- Topline data from 12-week double-blind period anticipated in second half of 2026.
- Builds on positive Phase 2b results; first Phase 3 study Voyage also recently launched.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025010802/0000950170-25-010802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017025010802/mnmd-20250130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-010802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer